https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
IOZK
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
IOZK2014-09-12 17:20:592019-02-12 19:53:44Verleihung des UNESCO-L’Oréal-Preises „Women in Science“
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2014-09-11 / Front Oncol 2014;4:224
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2014-09-11 / Front Oncol 2014;4:2242014-09-11 00:00:002021-11-15 16:55:17Multimodal cancer therapy involving oncolytic newcastle disease virus, autologous immune cells, and bi-specific antibodies
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
IOZK
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
IOZK2014-09-10 17:18:392019-02-12 17:19:00Artikel im Deutschen Ärzteblatt zum Thema: Tumorbiologie
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2014-05-13 / Cytotherapy 2014 Jul;16(7):946-64
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2014-05-13 / Cytotherapy 2014 Jul;16(7):946-642014-05-13 00:00:002021-11-15 13:30:25Development and validation of a fully GMP-compliant production process of autologous, tumor-lysate-pulsed dendritic cells
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2014-05-02 / Expert Rev Clin Immunol 2014 Jun;10(6):705-11
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2014-05-02 / Expert Rev Clin Immunol 2014 Jun;10(6):705-112014-05-02 00:00:002021-11-15 13:30:54Wilms‘ tumor gene 1 immunotherapy in pelvic gynecological malignancies
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2014-01-01 / Expert Rev Vaccines 2014 Jan;13(1):117-30
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2014-01-01 / Expert Rev Vaccines 2014 Jan;13(1):117-302014-01-01 00:00:002021-11-15 16:55:45Autologous tumor cell vaccines for post-operative active-specific immunotherapy of colorectal carcinoma: long-term patient survival and mechanism of function
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2013-11-12 / Expert Rev Neurother 2013 Dec;13(12):1395-406
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2013-11-12 / Expert Rev Neurother 2013 Dec;13(12):1395-4062013-11-12 00:00:002021-11-15 13:32:44Myeloid-derived suppressor cells in glioma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2013-11-06 / Oncoimmunology 2013 Dec;2(12):e27059
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2013-11-06 / Oncoimmunology 2013 Dec;2(12):e270592013-11-06 00:00:002021-11-15 13:33:23Dendritic cell-based immunotherapy in ovarian cancer
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2013-10-01 / Immunotherapy 2013 Oct;5(10):1043-6
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2013-10-01 / Immunotherapy 2013 Oct;5(10):1043-62013-10-01 00:00:002021-11-15 14:42:34Immunotherapy for high-grade glioma: how to go beyond Phase I/II clinical trials
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2013-09-01 / Anticancer Res. 2013 Sep;33(9):3855-9
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2013-09-01 / Anticancer Res. 2013 Sep;33(9):3855-92013-09-01 00:00:002021-11-15 14:43:00Immunological response after WT1 mRNA-loaded dendritic cell immunotherapy in ovarian carcinoma and carcinosarcoma
